Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits

Lipids in Health and Disease

Enqi Liu³  Jianglin Fan⁴  Sihai Zhao¹  Lijing Sun¹  Shoucui Gao¹  Yafeng Li¹  Ninghong Zhu¹  Hua Guan¹  Yulong Chen³  Yan Lin¹  Liang Bai¹  Yanli Wang² 

[1] Laboratory Animal Center, Xi’an Jiaotong University School of Medicine, Xi’an 710061, Shaanxi, China;Research Institute of Atherosclerotic Disease, Xi’an Jiaotong University Cardiovascular Research Center, Xi’an, Shaanxi, China;Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an 710021, Shaanxi, China;Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi 409-3898, Japan

关键词: Rabbits;    Atherosclerosis;    Cilostazol;    Probucol;    Atorvastatin;   

Others  :  1221309
DOI  :  10.1186/s12944-015-0083-5

 received in 2015-03-18, accepted in 2015-07-21,  发布年份 2015

【 摘 要 】

Background

Atherosclerotic cardiovascular disease is one of the major diseases that seriously impacts human health. Combined drug therapy may be efficacious in delaying the occurrence of cardiovascular events.

Aim

The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits.

Methods and Results

Thirty Japanese white rabbits were fed with a high cholesterol diet for 12 weeks, which was supplemented with either 0.005 % atorvastatin alone or 0.005 % atorvastatin plus 0.3 % probucol and 0.3 % cilostazol. Except for high-density lipoprotein cholesterol, no difference was found in plasma lipids among vehicle, statin, and the combined treatment group. However, atherosclerotic lesions were significantly reduced by statin treatment compared with vehicle. Moreover, we found that the anti-atherogenic effect of statin was further enhanced by the combined treatment, which was due to increased anti-inflammatory and anti-oxidant properties.

Conclusions

These data demonstrated that combined drug treatment exhibits potent athero-protective effects via pleiotropic functions, such as anti-inflammatory and anti-oxidative stress, which is independent of the lipid-lowering effect.

【 授权许可】

   
2015 Wang et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al.. ESC/EAS Guidelines for the management of dyslipidaemias. Rev Esp Cardiol. 2011; 64:1168.e1-1168.e60.
• [2]Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al.. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014; 129:e28-e292.
• [3]Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3:e442.
• [4]Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al.. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-1504.
• [5]Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al.. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359:1343-1356.
• [6]Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010; 160:785-794.
• [7]Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al.. ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis. 2007; 194:1-45.
• [8]Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002; 106:2041-2042.
• [9]Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL et al.. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108:426-431.
• [10]Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004; 109:II18-II26.
• [11]Wang ZH, Liu XL, Zhong M, Zhang LP, Shang YY, Hu XY et al.. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010; 50:311-319.
• [12]Arca M, Pigna G, Favoccia C. Management of statin-intolerant patient. Panminerva Med. 2012; 54:105-118.
• [13]Cooney MT, Dudina A, D’Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? Circulation. 2010; 122:300-310.
• [14]Keyamura Y, Nagano C, Kohashi M, Niimi M, Nozako M, Koyama T et al.. Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. PLoS One. 2014; 9:e96929.
• [15]Daugherty A, Zweifel BS, Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol. 1989; 98:612-618.
• [16]Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009; 207:16-23.
• [17]Weintraub WS. The vascular effects of cilostazol. Can J Cardiol. 2006; 22:56B-60B.
• [18]Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006; 109:366-398.
• [19]Chen YL, Zhao SH, Huang BQ, Wang YL, Li YF, Waqar AB et al.. Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits. Thromb Res. 2013; 132:565-571.
• [20]Fan JL, Watanabe T. Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol Ther. 2003; 99:261-282.
• [21]Satonin DK, Coutant JE. Comparison of gas chromatography and high-performance liquid chromatography for the analysis of probucol in plasma. J Chromatogr. 1986; 380:401-406.
• [22]Fu CJ, Tata PN, Okada K, Akiyama H, Bramer SL. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B. 1999; 728:251-262.
• [23]Liu EQ, Kitajima S, Higaki Y, Morimoto M, Sun HJ, Watanabe T et al.. High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits. Metabolism. 2005; 54:132-138.
• [24]Zhang CF, Zheng HD, Yu Q, Yang PG, Li YF, Cheng F et al.. A practical method for quantifying atherosclerotic lesions in rabbits. J Comp Pathol. 2010; 142:122-128.
• [25]Wang YL, Cheng F, Chen YL, Li YF, Zhao SH, Yu Q et al.. High-dose rosiglitazone is pro-atherogenic in cholesterol-fed rabbits. Atherosclerosis. 2012; 222:292-294.
• [26]Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Rosenfeld ME et al.. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994; 89:2462-2478.
• [27]Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W et al.. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995; 92:1355-1374.
• [28]Li S, Liang J, Niimi M, Waqar AB, Kang D, Koike T et al.. Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. J Atheroscler Thromb. 2014; 21:648-658.
• [29]Smith SC, Grundy SM. 2013 ACC/AHA Guideline Recommends Fixed-Dose Strategies Instead of Targeted Goals to Lower Blood Cholesterol. J Am Coll Cardiol. 2014; 64:601-612.
• [30]Wang YL, Bai L, Lin Y, Guan H, Zhu NH, Chen YL et al.. Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects. Histol Histopathol. 2014; 29:1593-1600.
• [31]Yu Q, Li YF, Wang YL, Zhao SH, Yang PG, Chen YL et al.. C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits. Histol Histopathol. 2012; 27:529-535.
• [32]Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ. Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation. 2011; 124:1382-1390.
• [33]Hirano K, Ikegami C, Tsujii K, Zhang Z, Matsuura F, Nakagawa-Toyama Y et al.. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol. 2005; 25:2422-2427.
• [34]Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T et al.. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997; 27:285-292.
• [35]Lau AK, Leichtweis SB, Hume P, Mashima R, Hou JY, Chaufour X et al.. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation. 2003; 107:2031-2036.
• [36]Oliveira HC, de Faria EC. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life. 2011; 63:248-257.
• [37]Sirtori CR. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention. Expert Opin Investig Drugs. 2011; 20:1543-1554.
• [38]Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG et al.. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009; 338:b2376.
• [39]Keizer HG. The “Mevalonate hypothesis”: a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids Health Dis. 2012; 11:149. BioMed Central Full Text
• [40]Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557-1565.
• [41]Sun HJ, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B et al.. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005; 167:1139-1148.
• [42]Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA. In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011; 62:209-218.
• [43]Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor- a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003; 105:705-716.
• [44]Liapikos TA, Antonopoulou S, Karabina SP, Tsoukatos DC, Demopoulos CA, Tselepis AD. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta. 1994; 1212(3):353-360.
• [45]Tsantila N, Karantonis HC, Perrea DN, Theocharis SE, Iliopoulos DG, Iatrou C et al.. Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration. Nutr Metab Cardiovasc Dis. 2010; 20:740-747.
• [46]Detopoulou P, Demopoulos CA, Karantonis HC, Antonopoulou S. Mediterranean diet and its protective mechanisms against cardiovascular disease: An insight into Platelet Activating Factor (PAF) and diet interplay. Annals of Nutritional Disorders and Therapy. 2015; 2:1-10.